Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
166 hedge funds and large institutions have $3.45B invested in Turning Point Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 79 increasing their positions, 44 reducing their positions, and 15 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
80% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 44
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
44% more capital invested
Capital invested by funds: $2.4B → $3.45B (+$1.05B)
5% more funds holding
Funds holding: 158 → 166 (+8)
1% less call options, than puts
Call options by funds: $1.75M | Put options by funds: $1.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$86.8M |
| 2 |
BlackRock
New York
|
+$28.7M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.6M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$10.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$26M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$20.6M |
| 3 |
DM
Deerfield Management
New York
|
-$12.2M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$9.61M |
| 5 |
N
Natixis
Paris,
France
|
-$8.38M |
TPTX Hedge Fund Activity: Q3 2020 in Review
166 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2020, worth a combined $3.45B — up 44% from $2.4B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TPTX positions and 15 closed out — a net gain of 8 holders — while 79 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $86.8M. The largest seller was Pictet Asset Management (UK), cutting an estimated $26M.
- 166 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2020, up from 158 in Q2 2020.
- Funds reported $3.45B of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2020, up 44% quarter-over-quarter.
- 23 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2020 and 15 closed out, a net change of +8 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q3 2020 was Fidelity Investments, an estimated $86.8M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2020 was Pictet Asset Management (UK), an estimated $26M sold.
Based on aggregated 13F filings for Q3 2020.